Mike Kelly, President and CEO of NervGen, brings over 30 years of pharmaceutical expertise to the table. He discusses groundbreaking advancements in nervous system repair, particularly regarding spinal cord injuries. The conversation dives into clinical trials for their promising drug candidate, NVG-291, and how new protocols might change the landscape of recovery. Mike also highlights the importance of biomarker analysis in indicating breakthroughs, and shares insights on the journey to FDA approval, emphasizing the impact on real-world treatment.

Mike Kelly, CEO of NervGen, leads the charge in peptide therapeutics aimed at repairing the central nervous system. He shares his transformation from a sales background to a biotech leader, emphasizing the importance of mentorship in understanding complex biopharma science. The discussion highlights NervGen's innovative strategies for tackling neurodegenerative diseases and the challenges of peptide manufacturing. Kelly also reflects on navigating startup dynamics, funding strategies, and the significance of collaboration in biopharma success.